JP2018506570A5 - - Google Patents

Download PDF

Info

Publication number
JP2018506570A5
JP2018506570A5 JP2017545544A JP2017545544A JP2018506570A5 JP 2018506570 A5 JP2018506570 A5 JP 2018506570A5 JP 2017545544 A JP2017545544 A JP 2017545544A JP 2017545544 A JP2017545544 A JP 2017545544A JP 2018506570 A5 JP2018506570 A5 JP 2018506570A5
Authority
JP
Japan
Prior art keywords
ophthalmic
ophthalmic pharmaceutical
oil
pharmaceutical formulation
dry eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017545544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506570A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/019207 external-priority patent/WO2016138049A1/en
Publication of JP2018506570A publication Critical patent/JP2018506570A/ja
Publication of JP2018506570A5 publication Critical patent/JP2018506570A5/ja
Pending legal-status Critical Current

Links

JP2017545544A 2015-02-24 2016-02-23 ドライアイ疾患及び他の眼障害の治療のための方法及び組成物 Pending JP2018506570A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562119857P 2015-02-24 2015-02-24
US62/119,857 2015-02-24
PCT/US2016/019207 WO2016138049A1 (en) 2015-02-24 2016-02-23 Methods and compositions for treating dry eye disease and other eye disorders

Publications (2)

Publication Number Publication Date
JP2018506570A JP2018506570A (ja) 2018-03-08
JP2018506570A5 true JP2018506570A5 (enExample) 2019-04-04

Family

ID=56692824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017545544A Pending JP2018506570A (ja) 2015-02-24 2016-02-23 ドライアイ疾患及び他の眼障害の治療のための方法及び組成物

Country Status (12)

Country Link
US (1) US9597328B2 (enExample)
EP (1) EP3261620B1 (enExample)
JP (1) JP2018506570A (enExample)
KR (1) KR20170132725A (enExample)
CN (1) CN107427459A (enExample)
AU (1) AU2016222902A1 (enExample)
BR (1) BR112017017448A2 (enExample)
CA (1) CA2976120A1 (enExample)
ES (1) ES2936394T3 (enExample)
MX (1) MX2017010544A (enExample)
RU (1) RU2691412C2 (enExample)
WO (1) WO2016138049A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US20070016256A1 (en) 2005-07-18 2007-01-18 Korb Donald R Method and apparatus for treating gland dysfunction
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US11478437B2 (en) * 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
WO2018212846A1 (en) * 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use
CA3080166A1 (en) * 2017-11-21 2019-05-31 Axerovision, Inc. Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
US11759472B2 (en) * 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
KR20250065422A (ko) 2017-12-15 2025-05-12 타르서스 파마수티칼스, 아이엔씨. 안검염을 치료하기 위한 이속사졸린 구충제 제제 및 방법
JP6653037B2 (ja) * 2018-03-30 2020-02-26 千寿製薬株式会社 水性液剤
JP6621955B2 (ja) * 2018-03-30 2019-12-18 千寿製薬株式会社 水性液剤
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
CA3115664A1 (en) * 2018-08-29 2020-03-05 Ocugen, Inc. Ophthalmic compositions and methods of use
KR20220084381A (ko) * 2019-12-10 2022-06-21 알콘 인코포레이티드 생분해성 중합체를 갖는 용해성 중합체 눈 삽입물
US20230302032A1 (en) * 2020-08-04 2023-09-28 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
CA3199736A1 (en) 2020-11-23 2022-05-27 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
CN116710087A (zh) * 2020-11-23 2023-09-05 美国商业眼科医疗器械公司 用于治疗眼部病症的制剂和方法
CN115645356A (zh) * 2022-11-21 2023-01-31 山东诺明康药物研究院有限公司 一种酒石酸溴莫尼定原位凝胶及其制备方法和应用
WO2025174723A1 (en) * 2024-02-12 2025-08-21 Selagine Inc. Ophthalmic composition comprising cethromycin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK3412U (sk) * 2002-07-01 2003-01-09 Unimed Pharma Spol Sro Očná inštalácia so zlepšenou stabilitou účinnej látky na báze brimomidínu
US20040088199A1 (en) * 2002-10-31 2004-05-06 Childress Allen B. Method of forming a business rule
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
WO2006004577A2 (en) * 2004-03-12 2006-01-12 Melbj Holdings, Llc Lubricant for the ocular surface
MX2009000885A (es) * 2006-07-25 2009-02-05 Osmotica Corp Soluciones oftalmicas.
US9125807B2 (en) * 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
CN101352441A (zh) * 2007-07-27 2009-01-28 肖正连 一种酒石酸溴莫尼定眼用即型凝胶
US20120003296A1 (en) * 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
CA2808307C (en) 2010-08-16 2022-06-21 Allergan, Inc. Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
US20120093876A1 (en) * 2010-10-13 2012-04-19 Aciex, Inc. Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
MX346312B (es) * 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.
EP2630952A1 (en) * 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid

Similar Documents

Publication Publication Date Title
JP2018506570A5 (enExample)
Lalu et al. Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions
RU2017129247A (ru) Способы и композиции для лечения болезни сухого глаза и других глазных заболеваний
US20220218669A1 (en) Compositions and methods for non-surgical treatment of ptosis
KR102701100B1 (ko) 친수성 약물을 함유하는 점안액으로부터의 방부제 제거
WO2019068763A1 (en) OPHTHALMIC COMPOSITIONS COMPRISING F6H8
JP2006176499A (ja) 眼疾患治療剤
TWI535441B (zh) 用以避免或治療乾眼症之含瑞巴派特或其前藥之口服藥物組成
JP2013237638A (ja) 眼科組成物
RU2017112930A (ru) Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза
KR101778004B1 (ko) 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
RU2670100C2 (ru) Офтальмическая композиция для цвиттерионных мягких контактных линз
Shirkhedkar et al. Herbal drugs for the treatment of ocular infections
KR20150119082A (ko) 국소 안구 진통제
AU2018323035B2 (en) Compositions providing improved eye comfort
JP2021105065A (ja) 異物感緩和点眼剤
US12311004B2 (en) Ophthalmic formulations and methods of use
US20250255915A1 (en) Ophthalmic formulations and methods of use
HK40028636A (en) Oxymetazoline for Topical Ophthalmic Administration and Uses Thereof
HK40031039A (en) Compositions providing improved eye comfort
HK40031039B (en) Compositions providing improved eye comfort
Baudouin Ocular surface assessment of glaucoma drug tolerance
HK1191223B (en) Compositions and methods for non-surgical treatment of ptosis
HK1191223A (en) Compositions and methods for non-surgical treatment of ptosis